METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS C AND AUTOIMMUNE LIVER DISEASES IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS Russian patent published in 2025 - IPC G01N33/68 G01N33/573 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to hepatology, laboratory diagnostics, and can be used for differential diagnosis of chronic hepatitis C (CHC) and autoimmune liver diseases (AILD) in patients with severe fibrosis and cirrhosis. Blood plasma is analysed for concentration of cytokines IL-10 in pg/ml, IL-17A in pg/ml and TNFα in pg/ml. Diagnosis in a patient with severe fibrosis and cirrhosis is established by comparing the obtained values with threshold values: at the first stage, TNFα concentration is estimated, value of which is more than or equal to 41.32 pg/ml requires a second stage for this patient, value less than 41.32 pg/ml requires a third stage for this patient. At the second stage, IL-10 concentration is assessed; if the value is less than 7.58 pg/ml, CHC is diagnosed, and if the value is more than or equal to 7.58 pg/ml, AILD is diagnosed. At the third stage, the IL-17A concentration is assessed; if the value is more than or equal to 3.29 pg/ml, AILD is diagnosed, and if the value is less than 3.29, CHC is diagnosed.

EFFECT: method enables differential diagnosis of chronic hepatitis C and autoimmune liver diseases, including autoimmune hepatitis and primary biliary cirrhosis, in patients with severe fibrosis and cirrhosis (F3-4), by determining three cytokines in blood plasma: IL-10, IL-17A, TNFα.

1 cl, 1 dwg, 3 ex